The FDA plans to issue guidance by the end of the year regarding drugmakers' marketing of approved drugs for unapproved uses. The guidance will address how drugmakers should respond to unsolicited requests for information about off-label uses and will contain a framework for how medical journal reprints that include off-label data may be distributed.

Related Summaries